Other than an association with HPV infection, little is known about the genetic alterations determining the development of penile cancer. Although penile cancer is rare in the developed world, it presents a significant burden in developing countries. Here, we report the findings of whole-exome sequencing (WES) to determine the somatic mutational landscape of penile cancer. WES was performed on penile cancer and matched germline DNA from 27 patients undergoing surgical resection. Targeted resequencing of candidate genes was performed in an independent 70 patient cohort. Mutation data were also integrated with DNA methylation and copy-number information from the same patients. We identified an HPV-associated APOBEC mutation signature and an NpCpG signature in HPV-negative disease. We also identified recurrent mutations in the novel penile cancer tumor suppressor genes CSN1(GPS1) and FAT1 Expression of CSN1 mutants in cells resulted in colocalization with AGO2 in cytoplasmic P-bodies, ultimately leading to the loss of miRNA-mediated gene silencing, which may contribute to disease etiology. Our findings represent the first comprehensive analysis of somatic alterations in penile cancer, highlighting the complex landscape of alterations in this malignancy. Cancer Res; 76(16); 4720-7. ©2016 AACR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302160PMC
http://dx.doi.org/10.1158/0008-5472.CAN-15-3134DOI Listing

Publication Analysis

Top Keywords

penile cancer
24
penile
7
cancer
7
csn1 somatic
4
somatic mutations
4
mutations penile
4
penile squamous
4
squamous cell
4
cell carcinoma
4
carcinoma association
4

Similar Publications

We present a case of a 66-year-old man with a three-year history of Gleason 10 prostate cancer (PCa), who presented with penile pain, erythema, and induration of the penile shaft. His cancer was treated with androgen deprivation therapy (ADT), radiotherapy, and apalutamide, resulting in PSA reduction; however, a solitary penile lesion persisted, necessitating radical penectomy. At 12 months post-surgery, PSA levels and magnetic resonance imaging findings remained stable, with no signs of metastasis.

View Article and Find Full Text PDF

Background: Inflatable penile prosthesis (IPP) insertion is recommended for the treatment of patients with Peyronie's disease (PD) and significant erectile dysfunction (ED); adjunctive procedures can be used for residual curvature after IPP placement.

Aim: To assess the management of penile curvature correction in PD patients undergoing IPP procedures within a large multinational, multicenter cohort.

Methods: A retrospective analysis was conducted on PD patients treated with IPP by 11 experienced prosthetic surgeons.

View Article and Find Full Text PDF

Introduction: Utilization of neoadjuvant systemic therapy (NAT) prior to radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is inconsistent, and optimal patient selection for NAT is unclear. The purpose of this study was to evaluate the clinical benefit of NAT in high grade UTUC undergoing RNU.

Materials And Methods: The UTUC Collaborative Network (UCAN) identified patients who underwent RNU for high grade UTUC between 2000 and 2022.

View Article and Find Full Text PDF

First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study.

J Natl Compr Canc Netw

December 2024

1Department of Urology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: The purpose of this study was to evaluate the efficacy and safety of PD-1 blockade combined with cisplatin and paclitaxel (TP)-based chemotherapy as first-line treatment for advanced penile squamous cell carcinoma (PSCC).

Patients And Methods: A retrospective review was performed of 32 eligible patients with high-risk stage IV (cN3M0-1) PSCC who received first-line PD-1 blockade combined with TP-based chemotherapy at 5 medical centers (2019-2023). Clinical responses were assessed using RECIST version 1.

View Article and Find Full Text PDF

Introduction And Objective: Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!